CABA News and Press, Cabaletta Bio Inc.

PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...

2024-06-28 13:42:28 ET Summary Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarka...

2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-14 14:05:13 ET More on Cabaletta Bio Cabaletta gets FDA orphan drug status for systemic sclerosis drug Seeking Alpha’s Quant Rating on Cabaletta Bio Historical earnings data for Cabaletta Bio Financial information for Cabaletta Bio Re...

– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...

Cabaletta Bio, Inc. (NASDAQ: CABA) is one of today's top gainers. The company's shares have moved 14.54% on the day to $12.68. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated ...

2024-06-10 10:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtbe...

2024-05-15 11:54:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cabaletta Bio (NASDAQ: CABA ) just reported results for the first quarter of 2024. Cabaletta Bio reported earnings per share of -51 cents. This was below the analyst estim...

2024-05-15 07:57:19 ET More on Cabaletta Bio Cabaletta gets FDA orphan drug status for systemic sclerosis drug Seeking Alpha’s Quant Rating on Cabaletta Bio Historical earnings data for Cabaletta Bio Financial information for Cabaletta Bio Re...